Stockscreener 앱 받기
6.37
0.63%
0.04
Cytosorbents Corp 주식(CTSO)의 최신 뉴스
CytoSorbents to present at H.C. Wainwright conf... - Pluang
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000 By Investing.com - Investing.com South Africa
Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000 - Investing.com
Cytosorbents Corp (CTSO) CEO bought more shares in the open market, adding to his stake - Stock Titan
CytoSorbents Corp (STU:HQE) Stock Earnings Transcripts - GuruFocus
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights - easternprogress.com
CytoSorbents to present at Moody Capital Soluti... - Pluang
CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference - The Globe and Mail
CytoSorbents Plans 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing - citybiz
CytoSorbents to implement 1-for-20 reverse stoc... - Pluang
CytoSorbents Announces Reverse Stock Split - Morningstar
CTSO Looks 61.4% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus
CytoSorb reduces severe bleeding by 37% in urge... - Pluang
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings - Yahoo Finance
Cytosorbents Earnings Call Balances Progress and Risk - TipRanks
Cytosorbents (CTSO) Financial Update: EPS Comes in Below Forecast; Market Follow-Through: Shares Finish 4.56% LowerEarnings Season Outlook - vinanet.vn
CytoSorbents (CTSO) wins approval for reverse split and director slate at 2026 meeting - Stock Titan
Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Cytosorbents Corp. R (HQE1.DU) Q1 FY2026 earnings call transcript - Yahoo Finance
Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q2 2026 Cytosorbents Corp Earnings Call Transcript - GuruFocus
Cytosorbents Corp (CTSO) Stock News Today - TradingKey
CytoSorbents posts $9.6M Q2 revenue, narrows cash burn and advances DrugSorb-ATR regulatory path - TradingView
Cytosorbents Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nea - GuruFocus
Is CytoSorbents Corp (CTSO) a Value Opportunity After Q2 Earning - GuruFocus
CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nearing Breakeven with Strong ... - finance.yahoo.com
Earnings call transcript: Cytosorbents posts modest Q2 2026 revenue beat - Investing.com
Cytosorbents : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Cytosorbents Corp reports results for the quarter ended June 30Earnings Summary - TradingView
CytoSorbents Q2 2026 earnings: Margins improve despite flat revenue - TradingKey
CytoSorbents: Q2 Earnings Snapshot - marketscreener.com
Cytosorbents Corp 2Q 2026: Revenue $9.63M, EPS ($0.07) — 10-Q Summary - TradingView
Cytosorbents Corp. R (HQE1.DU) Q2 FY2026 earnings call transcript - Yahoo Finance
CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update - PR Newswire
CytoSorbents (Nasdaq: CTSO) flags going concern as cash falls to $5.9M - Stock Titan
Cytosorbents Corp expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Cytosorbents Corp (CTSO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cytosorbents Corp (CTSO) Valuation: PE, PB & Fair Value Analysis - TradingKey
CytoSorbents Market Sentiment - Benzinga España
Cytosorbents Corp (CTSO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CTSO|Cytosorbents Corp|Price:0.360|Chg%:-0.001 - TradingKey
TradingKey - TradingKey
Cytosorbents Corp (CTSO) Cash Flow - TradingKey
CTSO|Cytosorbents Corp|Price:0.360| - TradingKey
Cytosorbents Corp (CTSO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CTSO|Cytosorbents Corp|Price:0.361|Chg%:-0.021 - TradingKey
CytoSorbents (CTSO) to Release Q2 Financial Results on July 30 - GuruFocus
CytoSorbents Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CytoSorbents (NASDAQ: CTSO) falls below Nasdaq $35M value test, faces 180-day cure - Stock Titan
CTSO | Cytosorbents Corp. Executive Compensation - Quiver Quantitative
[ARS] Cytosorbents Corp SEC Filing - Stock Titan
CytoSorbents (NASDAQ: CTSO) seeks reverse split to support Nasdaq listing - Stock Titan
CytoSorbents (NASDAQ: CTSO) Targets Major ICU & Cardiac Surgery Markets With Breakthrough Blood Purification Tech, Eyes 2026 Cash Flow Breakeven and FDA Approval 246 - Minichart
CytoSorbents schedules two FDA pre-submission meetings for ticagrelor and DOAC programs - TradingView
CytoSorbents (NASDAQ: CTSO) details DrugSorb-ATR FDA meetings, sales and cash flow goals - Stock Titan
Cytosorbents Corp (CTSO) Institutional Confidence - TradingKey
CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026 - Yahoo Finance
Cytosorbents Corp (CTSO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
2.29%
0.75%
자본화:
|
볼륨(24시간):